



Complete Genome Sequence of *Pseudomonas aeruginosa* K34-7, a Carbapenem-Resistant Isolate of the High-Risk Sequence Type 233

George Tairaoa,^{a,b} Ørjan Samuelsen,^{c,d} Tom Kristensen,^e  Ole Andreas Løchen Økstad,^{f,g}  Adam Heikal^{f,g}

^aDepartment of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand

^bDepartment of Biochemistry, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand

^cNorwegian National Advisory Unit on Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway

^dDepartment of Pharmacy, Faculty of Health Sciences, UiT—The Arctic University of Norway, Tromsø, Norway

^eDepartment of Biosciences, University of Oslo, Oslo, Norway

^fCentre for Integrative Microbial Evolution (CIME), Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway

^gLaboratory for Microbial Dynamics (LaMDa), Section for Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway

ABSTRACT Carbapenem-resistant *Pseudomonas aeruginosa* is defined as a “critical” priority pathogen for the development of new antibiotics. Here we report the complete genome sequence of an extensively drug-resistant, Verona integron-encoded metallo- β -lactamase-expressing isolate belonging to the high-risk sequence type 233.

Carbapenem-resistant *Pseudomonas aeruginosa* is a critical threat to public health (1). *P. aeruginosa* K34-7 belongs to sequence type 233 (ST233) and is an extensively drug-resistant (XDR), carbapenem-resistant clinical isolate expressing the Verona integron-encoded metallo- β -lactamase (VIM-2) (2). ST233 has been identified as a high-risk clone in both Mexico (3) and the United States (4). K34-7 was the first metallo- β -lactamase-producing *P. aeruginosa* isolate identified in Norway, and PCR analysis previously confirmed that the *bla*_{VIM-2} gene was contained within an unusual class 1 integron (GenBank accession number [FM165436](https://www.ncbi.nlm.nih.gov/nuccore/FM165436)) (2). As only one other *P. aeruginosa* ST233 complete genome has been published (5), this high-quality *P. aeruginosa* K34-7 genome will provide a valuable additional genomic resource for investigation of this high-risk ST.

Genomic DNA was prepared from a culture grown from a single colony using the Mo Bio DNeasy UltraClean microbial kit (Qiagen, USA) and sequenced on a PacBio RS II platform. A standard library of 20-kb fragments was prepared using the BluePippin preparative electrophoresis system (Sage Science, USA) with a 9-kb cutoff and sequenced on a single-molecule real-time (SMRT) cell using P6-C4 chemistry with 360-min movie-time chemistry. Additional whole-genome sequencing (WGS) was performed using an Illumina HiSeq sequencer. Genome assembly involved a *de novo* approach, using default HGAP 4 settings for the assembly of 96,269 PacBio reads (average length, 10,760 bp), before manual curation and validation. Iterative read mapping of Illumina sequences using custom settings in Geneious 10.1.3 (6) was used to identify assembly errors, primarily single-base insertions and deletions, and for variant correction (0.7 minimum variant frequency, 5 \times minimum coverage). Custom settings included allowed gaps (15% maximum/read and 15-bp maximum size); word and index word lengths of 18 and 13, respectively; and 20% maximum mismatch/read and maximum ambiguity of 4.

Received 22 June 2018 Accepted 29 June 2018 Published 2 August 2018

Citation Tairaoa G, Samuelsen Ø, Kristensen T, Økstad OAL, Heikal A. 2018. Complete genome sequence of *Pseudomonas aeruginosa* K34-7, a carbapenem-resistant isolate of the high-risk sequence type 233. *Microbiol Resour Announc* 7:e00886-18. <https://doi.org/10.1128/MRA.00886-18>.

Editor David A. Baltrus, University of Arizona

Copyright © 2018 Tairaoa et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Ole Andreas Løchen Økstad, aloechen@farmasi.uio.no, or Adam Heikal, adam.heikal@farmasi.uio.no.

The K34-7 genome consists of a 7,038,012-bp chromosome and one plasmid, pK34-7-1 (4,440 bp). A *P. aeruginosa* genomic island 5 (PAGI-5)-like hybrid (7) pathogenicity island (84,893 bp) and bacteriophage (38,832 bp) were found on the chromosome (positions 4154015 to 4238618 and 6469185 to 6508016, respectively). The XDR K34-7 phenotype is predominantly due to genes associated with three chromosomally located class 1 integrons, including genes imparting resistance to aminoglycosides [*aac(3)*, *aac(3)-I*, *aac(6')-II*, *aadA2*, and *aph(3')-IIb*], β -lactams (*bla*_{OXA-4'}, *bla*_{OXA-486'}, *bla*_{PDC-3'}, and *bla*_{VIM-2}), chloramphenicol (*catB*, *cmlA6*, and *floR*), trimethoprim (*dfrB5*), fosfomycin (*fosA*), sulfonamide (*sul1*), and tetracycline (*tetG*), as annotated by the PGAP pipeline (8). Additionally, *tetK*, encoding the tetracycline efflux pump TetK, is found on the small pK34-7-1 plasmid.

A region (1936000 to 2043700) of 12 direct tandem repeats (7,122 bp, 11.5 \times mean Illumina coverage) encodes a zonular occludens toxin, previously characterized in *Vibrio cholerae* (9, 10). Similar regions appear in other *P. aeruginosa* genomes but not in the ST233 *P. aeruginosa* PA83 genome (5). Additionally, *P. aeruginosa* K34-7 contains a type I-F CRISPR-Cas system (1656563 to 1664702), previously described in *P. aeruginosa* strain UCBPP-PA14 (11).

Complete high-quality bacterial genomes facilitate further research into mechanisms of resistance and their dissemination and aid in the development of new therapies for XDR infections.

Data availability. This complete genome project has been deposited at GenBank under the accession numbers [CP029707](#) and [CP029708](#).

ACKNOWLEDGMENTS

The sequencing service was provided by the Norwegian Sequencing Centre (<http://www.sequencing.uio.no>), a national technology platform hosted by the University of Oslo and supported by the "Functional Genomics" and "Infrastructure" programs of the Research Council of Norway and the Southeastern Regional Health Authorities.

We thank Ewa Jaroszewicz for technical support.

REFERENCES

- World Health Organization. 2017. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization, Geneva, Switzerland. <http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/>.
- Samuelsen Ø, Buarø L, Toleman MA, Giske CG, Hermansen NO, Walsh TR, Sundsfjord A. 2009. The first metallo- β -lactamase identified in Norway is associated with a TnIC-like transposon in a *Pseudomonas aeruginosa* isolate of sequence type 233 imported from Ghana. *Antimicrob Agents Chemother* 53:331–332. <https://doi.org/10.1128/AAC.00785-08>.
- Aguilar-Rodea P, Zúñiga G, Rodríguez-Espino BA, Olivares Cervantes AL, Gamiño Arroyo AE, Moreno-Espinosa S, de la Rosa Zamboni D, López Martínez B, Castellanos-Cruz MdC, Parra-Ortega I, Jiménez Rojas VLJ, Viguera Galindo JC, Velázquez-Guadarrama N. 2017. Identification of extensive drug resistant *Pseudomonas aeruginosa* strains: new clone ST1725 and high-risk clone ST233. *PLoS One* 12:e0172882. <https://doi.org/10.1371/journal.pone.0172882>.
- Perez F, Hujer AM, Marshall SH, Ray AJ, Rather PN, Suwantarant N, Dumford D, 3rd, O'Shea P, Domitrovic TNJ, Salata RA, Chavda KD, Chen L, Kreiswirth BN, Vila AJ, Haussler S, Jacobs MR, Bonomo RA. 2014. Extensively drug-resistant *Pseudomonas aeruginosa* isolates containing *bla*_{VIM-2} and elements of *Salmonella* genomic island 2: a new genetic resistance determinant in Northeast Ohio. *Antimicrob Agents Chemother* 58:5929–5935. <https://doi.org/10.1128/AAC.02372-14>.
- Döbelmann B, Willmann M, Steglich M, Bunk B, Nübel U, Peter S, Neher RA. 2017. Rapid and consistent evolution of colistin resistance in extensively drug-resistant *Pseudomonas aeruginosa* during morbidostat culture. *Antimicrob Agents Chemother* 61:e00043-17. <https://doi.org/10.1128/AAC.00043-17>.
- Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, Buxton S, Cooper A, Markowitz S, Duran C, Thierer T, Ashton B, Meintjes P, Drummond A. 2012. Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. *Bioinformatics* 28:1647–1649. <https://doi.org/10.1093/bioinformatics/bts199>.
- Battle SE, Meyer F, Rello J, Kung VL, Hauser AR. 2008. Hybrid pathogenicity island PAGI-5 contributes to the highly virulent phenotype of a *Pseudomonas aeruginosa* isolate in mammals. *J Bacteriol* 190:7130–7140. <https://doi.org/10.1128/JB.00785-08>.
- Tatusova T, DiCuccio M, Badretdin A, Chetvernin V, Nawrocki EP, Zaslavsky L, Lomsadze A, Pruitt KD, Borodovsky M, Ostell J. 2016. NCBI prokaryotic genome annotation pipeline. *Nucleic Acids Res* 44:6614–6624. <https://doi.org/10.1093/nar/gkw569>.
- Di Pierro M, Lu R, Uzzau S, Wang W, Margaretten K, Pazzani C, Maimone F, Fasano A. 2001. Zonula occludens toxin structure-function analysis: identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain. *J Biol Chem* 276:19160–19165. <https://doi.org/10.1074/jbc.M009674200>.
- De Magistris MT. 2006. Zonula occludens toxin as a new promising adjuvant for mucosal vaccines. *Vaccine* 24:S60–S61. <https://doi.org/10.1016/j.vaccine.2005.01.123>.
- Heussler GE, Miller JL, Price CE, Collins AJ, O'Toole GA. 2016. Requirements for *Pseudomonas aeruginosa* type I-F CRISPR-Cas adaptation determined using a biofilm enrichment assay. *J Bacteriol* 198:3080–3090. <https://doi.org/10.1128/JB.00458-16>.